



Rhythm Biosciences

An ASX Life Sciences Growth Opportunity

4TH JUNE 2026

ASX: RHY

Disclaimer



This presentation has been prepared by **Rhythm Biosciences Limited** (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Rhythm makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. Rhythm and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Rhythm. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.



Detecting cancer earlier to save lives

Rhythm Biosciences is an ASX listing company building precision diagnostics platform focused on earlier cancer detection, risk assessment and improve patient outcomes.

COLOSTAT®

Non-invasive blood-based
bowel cancer detection test



Assessing cancer risk before
symptoms appear

Rhythm is positioned at the intersection of precision medicine, preventative health care and scalable diagnostics.



Cancer is often detected too late

15,500+



new colorectal cancer cases diagnosed every year in Australia

>50%



Diagnosed as late-stage disease – Stages III or IV

10%



5-year survival rate when diagnosed at Stage IV


Earlier detection significantly improves survival outcomes and lowers treatment costs.




Earlier diagnosis changes outcomes

The need for cancer diagnostics is to move to earlier, simpler and more accessible disease detection.

Diagnoses at Stage I or II only represent less than half of all CRCs diagnosed:




Disease treatment costs increase with later stage[#]



McGarvey et al. BMC Health Services Research (2022) 22: 1155


Missed detection of early-stage CRC results in poor survival rates



5-year survival rates in patients with CRC in US, UK and Australia

Two complementary platforms. One precision cancer strategy.

Rhythm is building a scalable precision diagnostics ecosystem across the cancer care pathway.



Risk Assessment

Genomic cancer risk assessment

Identify elevated risk before symptoms emerge

COLOSTAT®*

COLOSTAT®

Disease Screening

Blood-based cancer detection

Improve screening accessibility and compliance

Building the future of precision cancer diagnostics:

- Earlier cancer detection
- Improved patient outcomes
- More personalised healthcare
- Better screening participation
- Scalable precision diagnostics

Supporting earlier detection through risk assessment and screening

geneType™ helps identify elevated cancer risk, supporting more targeted ColoSTAT® screening and earlier intervention.

COLOSTAT[®]

A blood-based colorectal cancer detection platform designed to aid effective early diagnosis.

ColoSTAT[®]: Supporting Colorectal Cancer Triage

Supporting colonoscopy decisions for symptomatic patients underserved by traditional methods



Avoidance of existing screens

Many patients avoid or decline traditional stool-based screening tests



Unsuitable for colonoscopy

Not all patients are suitable candidates for invasive procedures



Healthcare system bottlenecks

Long wait times create delays in diagnosis and treatment pathways




Accessibility challenges

Regional and underserved communities face limited screening access


Global Triage Opportunity

22M annual tests¹



Long Term Screening Opportunity

~400M eligible individuals annually²



¹40% of WW annual colonoscopy procedures, ² screening age, tested every two years, Unscreened based on reported compliance

Scaling ColoSTAT[®] Commercial Adoption

Clinically validated. Partner-enabled. Commercially scalable.



Target Market

Accessible, non-invasive cancer detection

- Patients underserved by traditional CRC testing methods
- Patients unable to access colonoscopy

~800,000 annual colonoscopy procedures in Australia

Commercial Channels

National healthcare engagement pathway

Primary Care

- GPs supporting earlier detection pathways

Specialist Care

- Diagnostic and referral pathway engagement

~41,000 healthcare professionals across Australia

Commercial Validation

Supporting physician confidence

- Supporting physician confidence and long-term adoption
- Published clinical and health economic evidence

Designed to support reimbursement pathways

Strategic Partnership-Led Commercial Expansion

National collection infrastructure supporting scalable ColoSTAT[®] rollout.



Testing, analytics and commercial execution



Collection network and patient access



Personalised cancer risk assessment designed to support earlier detection and prevention.

Predicting cancer risk before symptoms appear



Combines genomic and clinical data to support personalised prevention and screening pathways.

Clinically validated precision cancer risk assessment platform

Validated across six cancer indications with data from 100,000s of individuals


Personalised using genomic and clinical patient data

Commercially available in Australia and the United States



Personalised cancer risk assessment at scale

Predicting cancer risk before symptoms appear



Genotype Clinical Applications

- Individualised patient care
- Primary care
- Specialty care services
- Imaging clinics, urologists, endoscopy clinics, family history/genetics clinics,
- Institutional/payor level care
- Self-insured employers
- US private payors
- Government sponsored care

Genotype Segmentation

	Worried well – Proactive Preventers	Active Risk Assessors – Actively engaged in assessment	At Higher Risk – Seeking more information
Summary	A desire to understand their risks.	Encounter a reason to believe their risk is higher than average – typically age.	Urgency in need to assess risk. Available information unsatisfactory.
Use case	Otherwise, healthy but intervene to ensure longer health span.	Are engaged in population screening initiatives due to age, family or clinical history.	Possibly symptomatic or considered high risk. Reflex test for negative mutation testing or negative biopsy.

Genotype Market Size

(potential tests)

Total for 11 Markets = 276m¹



¹. Total market size for 11 developed markets: AUS, USA, JPN, DEU, UK, FRA, ITA, KOR, ESP, CAN, NLD. References available on request

Scaling Commercial Adoption



Genetype Target Segments



Oncology Portfolio Focus



- Breast*
- Prostate
- Colorectal*
- Ovarian
- Melanoma
- Pancreatic*

* Rhythm protein biomarker program overlap

Channel Strategy



- Health Care Professionals – B2B
- Strategic partners/ Enterprise accounts - B2B2C

Competition



Geographical Priorities



Strategic Partners





Commercial-stage cancer diagnostics platforms entering a significant growth phase.

Why Rhythm, Why Now?



Dual-platform precision diagnostics strategy

- Combining earlier cancer detection and personalised risk assessment
-

Commercialisation underway

- Commercial validation, partnerships and rollout progressing across several markets
-

Large addressable markets

- Exposure to growing global cancer diagnostics demand
-

Multiple near-term catalysts

- Commercial expansion through partnerships
-

Experienced diagnostics leadership

- Global expertise across diagnostics, genomics and healthcare commercialisation

Rhythm at a glance

Building a scalable precision diagnostics platform

Corporate Snapshot

3rd June 2026

ASX Code	RHY
Share Price	\$0.115
Shares on Issue	353.9M
Unlisted & Listed Options	74.1M
Market Capitalisation	\$38.9M
Cash in Bank (31 March 2026)	\$1.305M
Top 20 Shareholders	41.3%



RISK ASSESSMENT

geneType™

Personalised cancer risk assessment designed to support earlier detection and prevention.

ACCESSIBLE DETECTION

ColoSTAT®

A blood-based colorectal cancer detection platform designed to improve accessibility, compliance and earlier diagnosis.

Near-Term Growth Catalysts

Positioned for the next phase of commercial expansion and international growth.



PRODUCT	MILESTONE	DESCRIPTION	COMPLETION DATE
ColoSTAT®	Scaling commercial footprint	Activation of 4Cyte collection centres	Q4 FY2026
geneType™	geneType™ strategic partnerships	Establishment of key international and domestic commercial partners	Ongoing from Q3 FY2026
ColoSTAT®	ColoSTAT® Access Program	Complete enrolment for the ColoSTAT® Access Program	Q3 FY2026
ColoSTAT®	ColoSTAT® MBS Strategy	Complete strategy design for submission to MSAC	Q4 FY2026
geneType™	geneType™ menu expansion	Prototype of lung cancer geneType™ complete	Q4 FY2026
ColoSTAT®	International expansion: UK	Completion of first phase of NHS ColoSTAT® evaluation	Q4 FY2026
ColoSTAT®	International Expansion	Establish ColoSTAT® commercialisation partner beyond Australia and UK	Q1 FY2027

Team

Experienced diagnostics leadership executing the next phase of commercial growth



David Atkins, PhD
CEO & MD

Former CEO of Congenica (UK) & Synevo Diagnostics, Sr. Executive at Johnson & Johnson and Danaher.

Founder of Veridex – cancer molecular and cellular diagnostics (USA).

Experience in product development and commercial leadership in the global medical device and diagnostic industry. Also, an active member of BioNSW and InGeNA.



Sue MacLeman
Non-Executive Director

30 years in Pharma, Biotech and Medtech including Amgen, BMS and Merck and SME's.

Experienced Board member, former CEO of NASDAQ, ASX, & AIM entities. Currently Chair of Medicines Australia, NED & Chair at Viral Vector Manufacturing Facility, Smartways Logistics, Healthcare Translation Group, & OMICO & member of the National Research Infrastructure (NRI) Advisory Group.



Gavin Fox-Smith
Non-Executive Chairman

38 years as a leader and champion of Medical Technology in Australia/NZ and Asia.

Gavin is Chair of ANDHealth (Australia's National Digital Health Initiative), Board Director for Bowel Cancer Australia and Board Director for SAN Foundation.

Gavin was previously CEO of Omnigon, a private Australian company in the Ostomy Care market.



Jackson Jones
Chief Commercial Officer



Nir Dvorski
Chief Operations Officer



Erika Spaeth, PhD
Director of Genotype Clinical & Scientific Affairs



Andy Feber, PhD
Director of Diagnostic Clinical & Scientific Affairs



Gary Goh
Head of Laboratory Operations and RA/QA



Andrea Steele
General Counsel





Thank you!

David Atkins, PhD
CEO & MD

david.atkins@rhythmbio.com

www.rhythmbio.com